AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals
AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge in total revenue, reaching $54.1 billion. This ... Read More
Hutchmed secures priority review in China for ORPATHYS and TAGRISSO combination therapy
Hutchmed (China) Limited has achieved a significant milestone with the acceptance of its New Drug Application (NDA) by China’s National Medical Products Administration (NMPA) for ... Read More
EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a ... Read More
Genprex begins dosing of phase 1/2 trial of REQORSA, Tagrisso combo
Genprex has dosed the first patient in the Acclaim-1 phase 1/2 clinical trial of REQORSA immunogene therapy candidate in combination with Tagrisso (osimertinib) in a ... Read More
AstraZeneca secures extended FDA approval for Tagrisso as adjuvant treatment in early-stage lung cancer
AstraZeneca has announced a significant breakthrough with the United States Food and Drug Administration (FDA) granting extended approval for its drug Tagrisso (osimertinib) as an ... Read More
AstraZeneca’s Tagrisso secures FDA breakthrough therapy designation for first-line treatment of NSCLC
AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the ... Read More